London -- Collaboration between the PETA International Science Consortium Ltd., industry, government, and nonprofit groups has resulted in a 17-part free webinar series highlighting modern non-animal testing approaches for assessing the toxicity of inhaled substances. The webinar presentations, released online today, detail the ways in which cutting-edge computational models and human cell-based testing systems can be used to reduce and replace the use of animals in inhalation testing.
Among the organizations represented are 3M Company, AlveoliX, The Dow Chemical Company, Epithelix, Fraunhofer ITEM, the Institute for In Vitro Sciences, MatTek, Syngenta, ToxStrategies, Philip Morris International, Health Canada, the Luxembourg Institute of Science and Technology, and VITROCELL.
"These webinars showcase the expertise of leading scientists and provide researchers worldwide with an in-depth understanding of inhalation testing approaches that do not use animals and that better protect human health," says Consortium director Dr. Amy Clippinger.
The series is part of the Consortium's numerous collaborative efforts aimed at replacing the use of animals in inhalation toxicity tests with methods that are both animal-free and more human-relevant.
The PETA International Science Consortium Ltd. works to accelerate the development, validation, and global implementation of alternatives to animal testing. It was established in 2012 to coordinate the scientific and regulatory expertise of its members--PETA U.K., PETA U.S., PETA France, PETA Germany, PETA India, PETA Netherlands, PETA Asia, and PETA Australia.